Medicare Advantage - August 2021 Medical Policies and Utilization Management Guidelines Update
Please note, this communication applies to Healthy Blue + Medicare℠ (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).
The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.
Please share this notice with other members of your practice and office staff.
To view a guideline, visit https://medpol.providers.amerigroup.com/green-provider/medical-policies-and-clinical-guidelines.
Notes/Updates:
Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
- *CG-SURG-112 — Carpal Tunnel Decompression Surgery
- Outlines the Medically Necessary and Not Medically Necessary criteria for carpal tunnel decompression surgery
- *CG-SURG-113 — Tonsillectomy with or without Adenoidectomy for Adults
- Outlines the Medically Necessary and Not Medically Necessary criteria
- *DME.00043 — Neuromuscular Electrical Training for the Treatment of Obstructive Sleep Apnea or Snoring
- The use of a neuromuscular electrical training device is considered Investigational & Not Medically Necessary for the treatment of obstructive sleep apnea or snoring
- *GENE.00058 — TruGraf Blood Gene Expression Test for Transplant Monitoring
- TruGraf blood gene expression test is considered Investigational & Not Medically Necessary for monitoring immunosuppression in transplant recipients and for all other indications
- LAB.00040 — Serum Biomarker Tests for Risk of Preeclampsia
- Serum biomarker tests to diagnosis, screen for, or assess risk of preeclampsia are considered Investigational & Not Medically Necessary
- *LAB.00042 — Molecular Signature Test for Predicting Response to Tumor Necrosis Factor Inhibitor Therapy
- Molecular signature testing to predict response to Tumor Necrosis Factor inhibitor (TNFi) therapy is considered Investigational & Not Medically Necessary for all uses, including but not limited to guiding treatment for rheumatoid arthritis
- *OR-PR.00007 — Microprocessor Controlled Knee-Ankle-Foot Orthosis
- Outlines the Medically Necessary and Not Medically Necessary criteria for the use of a microprocessor controlled knee-ankle-foot orthosis
- *SURG.00032 — Patent Foramen Ovale and Left Atrial Appendage Closure Devices for Stroke Prevention
- Added Medically Necessary statement for transcatheter closure of left atrial appendage (LAA) for individuals with non-valvular atrial fibrillation for the prevention of stroke when criteria are met
- Revised Investigational & Not Medically Necessary statement for transcatheter closure of left atrial appendage when the criteria are not met
- *SURG.00077 — Uterine Fibroid Ablation: Laparoscopic, Percutaneous, or Transcervical Image Guided Techniques
- Added Medically Necessary statement on use of laparoscopic or transcervical radiofrequency ablation
- Added Not Medically Necessary statement on use of laparoscopic or transcervical radiofrequency ablation when criteria in Medically Necessary statement are not met
- Removed laparoscopic radiofrequency ablation from Investigational & Not Medically Necessary statement
- Removed Investigational & Not Medically Necessary statement on radiofrequency ablation using a transcervical approach
Medical Policies
On August 12, 2021, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Blue Cross NC. These guidelines take effect January 17, 2022.
PUBLISH DATE | MEDICAL POLICY # | MEDICAL POLICY TITLE | NEW OR REVISED |
---|---|---|---|
10/6/2021 | *DME.00043 | Neuromuscular Electrical Training for the Treatment of Obstructive Sleep Apnea or Snoring | New |
10/6/2021 | *GENE.00058 | TruGraf Blood Gene Expression Test for Transplant Monitoring | New |
10/6/2021 | *LAB.00040 | Serum Biomarker Tests for Risk of Preeclampsia | New |
10/6/2021 | *LAB.00042 | Molecular Signature Test for Predicting Response to Tumor Necrosis Factor Inhibitor Therapy | New |
10/6/2021 | *OR-PR.00007 | Microprocessor Controlled Knee-Ankle-Foot Orthosis | New |
8/19/2021 | *SURG.00032 | Patent Foramen Ovale and Left Atrial Appendage Closure Devices for Stroke Prevention | Revised |
8/19/2021 | *SURG.00077 | Uterine Fibroid Ablation: Laparoscopic, Percutaneous or Transcervical Image Guided Techniques | Revised |
8/19/2021 | SURG.00119 | Endobronchial Valve Devices | Revised |
8/19/2021 | SURG.00121 | Transcatheter Heart Valve Procedures | Revised |
Clinical UM Guidelines
On August 12, 2021, the MPTAC approved the following Clinical UM Guidelines applicable to Blue Cross NC. These guidelines adopted by the medical operations committee for our members on September 23, 2021. These guidelines take effect January 17, 2022.
PUBLISH DATE | CLINICAL UM GUIDELINE # | CLINICAL UM GUIDELINE TITLE | NEW OR REVISED |
---|---|---|---|
10/6/2021 | *CG-SURG-112 | Carpal Tunnel Decompression Surgery | New |
10/6/2021 | *CG-SURG-113 | Tonsillectomy with or without Adenoidectomy for Adults | New |
10/6/2021 | CG-DME-44 | Electric Tumor Treatment Field (TTF) | Revised |
8/19/2021 | CG-GENE-22 | Gene Expression Profiling for Managing Breast Cancer Treatment | Revised |
8/19/2021 | CG-MED-55 | Site of Care: Advanced Radiologic Imaging | Revised |
8/19/2021 | CG-SURG-82 | Bone-Anchored and Bone Conduction Hearing Aids | Revised |
For more information, visit Healthy Blue + Medicare.
BNCCARE-220-21 October 2021
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.